Why the study?
Does adjunctive thrombolytic therapy improve success rates or reduce complications in patients undergoing percutaneous transluminal coronary angioplasty?
Does adjunctive thrombolytic therapy improve success rates or reduce complications in patients undergoing percutaneous transluminal coronary angioplasty?
Adjunctive thrombolytic therapy during percutaneous transluminal coronary angioplasty does not offer clear benefits in success or restenosis rates and may increase complications in certain patient subsets.
Answers are grounded in this paper and cite their sources.
Adjunctive thrombolysis warrants avoidance in unstable angina and offers no clear benefit in elective PCI or MI; leaves open definitive restenosis trials.
Adjunctive thrombolysis has not been shown to improve angioplasty success or complication rates in elective angioplasty or myocardial infarction and may be detrimental in unstable angina. Thrombolysis of chronically occluded vessels achieves recanalization at a rate comparable to conventional angioplasty and is associated with a high rate of complications and limited long-term patency. Thrombolysis administered for thrombus or acute occlusion complicating angioplasty usually achieves coronary artery patency but is unable to forestall complications in many cases. A benefit of thrombolysis in reducing restenosis has not been conclusively demonstrated.
No takes yet. Share an insight, caveat, or question.
Vaitkus et al. (1994) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: